Veenat (Imatinib Mesylate)

Facts of VEENAT

  • Brand Name: VEENAT
  • Medicine Name: Imatinib Mesylate
  • Company Name: Natco Pharma
  • Supplied as: 100mg and 400mg. 10 tablets in one strip.
Get Price

Description

To Find:

  • Veenat availability
  • Different brands of Imatinib Mesylate
  • Imatinib Mesylate supplier/Exporters / Distributor / Wholesaler

Uses of Imatinib:

Veenat contains imatinib and is a famous medicine called protein tyrosine kinase inhibitor. This medication is used to treat cancer. Specifically, it is used for chronic myelogenous leukemia treatment (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.

List of substitutes for Veenat 400 mg Tablet

  • Altanib 400 mg Tablet (Alkem Laboratories Ltd.)
  • Cadinib 400 mg Tablet (Cadila Pharmaceuticals Ltd.)
  • Mitinab 400 mg Tablet (Glenmark Pharmaceuticals Ltd.)

How long is Imatinib taken?

Treatment should be continued as long as the patient continues to benefit.

How Does Imatinib Works?

Imatinib (Veenat) is a specific protein-tyrosine kinase inhibitor (TKI) which mainly works by inhibiting the bcr-abl (a tyrosine kinase), the constitutive abnormal tyrosine kinase formed by the Philadelphia chromosomes abnormality in the CML. Imatinib basically inhibits the proliferation and it also induces apoptosis in bcr-abl positive cell lines as well as maiden or fresh leukemic cells from the Philadelphia chromosome positive chronic myeloid leukemia. Imatinib also inhibits the colony formation in the assays using ex vivo peripheral blood and also samples of bone marrow from the CML patients.

In the Vivo, imatinib inhibits the growth of tumor of bcr-abl transfected murine myeloid cells as well as bcr-abl positive leukemia lines derived from the CML patients in the blast crisis. It is also an specific inhibitor of the receptor tyrosine kinases for the PDGF (platelet-derived growth factor) and stem cell factor (SCF), c-kit, and inhibits PDGF- and cellular events of SCF-mediated. Moving on vitro, this medication inhibits the proliferation and also induces the apoptosis in the GIST cells, which mainly express an activating c-kit mutation.

What kind of drug is Imatinib?

Imatinib (Veenat generic) is a type of cancer growth blocker called a tyrosine kinase inhibitor (TKI).

Side effects of Imatinib: Certain side effects may occur when you are on this medication. These comprise diarrhoea, change in amount of urine, loss of appetite, dark coloured urine, unusual bleeding, weakness, tiredness, vomiting, etc

Veenat FDA approval: Imatinib was approved for medical use in the United States in 2001. Imatinib cost is quite decent as well as affordable.

Additional Information

What is VEENAT (Imatinib Mesylate 100mg and 400 mg)?


VEENAT is indicated for the treatment of:


  • Newly diagnosed adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Follow-up is limited to 5 years

  • Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after the failure of interferon-alpha therapy

  • Pediatric patients with Ph+ CML in chronic phase who are newly diagnosed or whose disease has recurred after stem cell transplant or who are resistant to interferon-alpha therapy.

  • Adult patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

  • Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements

  • Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with cKit mutational status unknown

  • Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown

  • Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)

  • Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST).

Precautions


  • This medicine should not be used until prescribed by your doctor. It is also not prescribed by the doctor if you have ever suffered with low blood platelets level, swelling, low white blood cells, bone marrow, pulmonary fibrosis, etc.

  • Veenat is kind of a prescription medication and must be used under the proper medical guidance as well as advice. Never share or exchange the medicine with someone else.

  • Use of imatinib in prepubescent children can delay the normal growth.

  • Cytopenias, particularly anemia, neutropenia, and thrombocytopenia, have occurred. Should be managed with the dose reduction or interruption and in some rare cases discontinuation of treatment. Complete blood counts should be performed weekly for the initial month, biweekly for the next (second) month, and then periodically.

  • Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. Closely monitor TSH levels in such patients.

  • Severe congestive heart failure and left ventricular dysfunction have been reported, particularly in patients with comorbidities and risk factors. Patients who are with cardiac disease or risk factors for cardiac failure must be monitored as well as treated.

Interactions: Patients must be instructed not to take any kind of other medications, including over-the-counter drugs such as acetaminophen or herbal products without the consent of their pharmacist or healthcare provider first. Examples of other medications that should not be taken with Veenat are warfarin, erythromycin, and phenytoin. Patients should also be advised to tell their doctor if they are taking or plan to take iron supplements. Patients should also avoid grapefruit juice and other foods known to inhibit CYP3A4 while taking Veenat.


Overdose: Medical experience with imatinib overdose is limited. Treatment is supportive. Imatinib is highly plasma protein-bound: dialysis is unlikely to be helpful in removing imatinib.


Missed Dose: If you are taking imatinib once a day and miss a dose, take it as soon as you can if it is within 12 hours of the missed dose. If you are taking imatinib twice a day, take it as soon as you can if it is within 6 hours of the missed dose. Otherwise, skip the missed dose and go back to your usual dosing times. Let your healthcare provider know about the missed dose.

Commonly asked questions

What is the best price of VEENAT?


Please contact +91-8130290915 for VEENAT 100 mg and 400 mg .
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.


Where can I Buy VEENAT 400 mg online?


The Indian Pharma connects buyers with the supplier who can ship VEENAT (Imatinib Mesylate 100 mg and 400 mg) to any country of the world as per the buyer’s requirement and Government regulations of the country. VEENAT is manufactured by Natco Pharma.


The Indian Pharma provides options for choosing exporter and supplier of cancer treatment medicines. We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.


VEENAT 100mg & VEENAT 400mg availability:


VEENAT is a pharmaceutical drug that legally requires a medical prescription to be dispensed.


The Indian Pharma can facilitate the supply of VEENAT to all locations in the world and in India after fulfilling the legal requirement (if applicable).


Note:-